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Available online 24 October 2011Abstract In this article, an analysis of data on women directors on the boards of Indian
companies is followed by an interview with a first generation woman entrepreneur, Kiran Ma-
zumdar Shaw, head of the bio-pharma company, Biocon Ltd.
Empirical evidence suggests that though women directors on Indian corporate boards show
an increase both in numbers and in percentage terms, they are very much behind men. Women
are also less well represented on Indian corporate boards as compared to other countries.
Family ties, public sector employment and private sector banks are major sources of director-
ships for women. There are very few first generation women entrepreneurs in India. Though
initial thresholds are higher for women to achieve success, the problems they face afterwards
are similar to problems faced by successful men. India has a long way to go before women can
catch up with men in the corporate world.Background
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A database of the composition of the boards of directors
of 166 Indian companies for the period 1995e2007 has
been created.1 The study aims to understand and inter-
pret the patterns of cross linkages between the directors
on the boards of these 166 companies.
This study links up with a study carried out at the
National Institute of Advanced Studies (NIAS) on women
who had chosen scientific careers and what had happened1 The number of companies chosen was dependent on the number
of companies and the years for which the BOD data was available in
a digitally downloadable way. We would have ideally liked to have
collected data at least from 1991 when the economic reform process
in India was initiated. However this reduced significantly the size of
our sample. See Chandrashekar & Muralidharan, IIMB Working Paper
No. 324, 2010.
Table 1 Women directorships on board of directors (1995e2007) e Findings.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
Total women directorships 29 36 37 38 45 39 50 48 54 55 60 63 67 621
Total directorships 1745 1816 1804 1769 1809 1771 1826 1836 1840 1822 1802 1840 1845 23525
Total men directorships 1716 1780 1767 1731 1764 1732 1776 1788 1786 1767 1742 1777 1778 22904
Number of women who are
directors
28 33 31 35 39 33 43 38 42 44 48 52 51 517
Number of individuals who
are directors
1472 1532 1525 1497 1512 1469 1515 1525 1520 1519 1507 1556 1545 19694
Maximum directorships held
by a woman
2 3 5 3 3 3 3 3 3 3 3 3 3 NA
Number of women
chairpersons
2 3 2 3 2 2 2 2 3 3 3 2 3 NA
Percentage women
directorships
1.66% 1.98% 2.05% 2.15% 2.49% 2.20% 2.74% 2.61% 2.93% 3.02% 3.33% 3.42% 3.63% 2.64%
Percentage women who
were directors
1.90% 2.15% 2.03% 2.34% 2.58% 2.25% 2.84% 2.49% 2.76% 2.90% 3.19% 3.34% 3.30% 2.63%
Number of Directorships per
woman Director
1.04 1.09 1.19 1.09 1.15 1.18 1.16 1.26 1.29 1.25 1.25 1.21 1.31 NA
Number of directorships per
man Director
1.19 1.19 1.18 1.18 1.20 1.21 1.21 1.20 1.21 1.20 1.19 1.18 1.19 NA
224 A. Kurup et al.to them (Kurup et al., 2010). A survey ofwhatwas available in
the public domain revealed that there were no comprehen-
sive studies on women in the Indian corporate world.2 Since
the data set that we had created for the study of cross link-
ages among boards of directors permitted us to clearly
identifywomenwhowere on the boards of the 166 companies
in our database we had readily available data that would
enable us to carry out a study on women in the corporate
world. Such a study would complement the study on women
in science and other gender related studies in India.
This perspectives note presents the preliminary findings
of our study on women in the corporate world and also adds
a missing dimension to the study through an interview with
Ms Kiran Mazumdar Shaw, a very successful first generation
woman entrepreneur and the Chairperson of Biocon Ltd.
Approach
The data for women directors on the board of directors of
the 166 companies in our data set was extracted from the
comprehensive data set on directorships obtained from the
published annual reports of these companies.3 Data for the
years from 1995 to 2007 was analysed. The observed trends
are presented in the first part of the article.
Based on the broad patterns that we could infer from
the first part of our study we widened the scope of the2 As we were analysing our collected data there was a study put
out by the Standard Chartered Bank that looked at this issue. Our
study not only provides an additional historical perspective but adds
several additional dimensions to our understanding of this issue.
Together the studies provide a more comprehensive understanding
of this phenomenon. See Banerji et al., 2010.
3 We initially tried to get data on the board of directors for the top
500 companies from available data sources selling data on
a commercial basis. On checking some samples of such data we
found quite a few instances of erroneous data. We therefore had to
create a data set from published annual reports available with
several commercial suppliers of these reports.project to look at some other aspects. We identified
women who appeared to be influential and looked in
greater detail at their profiles. We also tried to identify
from our sample those organisations and institutions that
seemed to provide more opportunities for advancement of
women and tried to understand the reasons for their
differential approach. Since family connections seemed to
matter we also tried to look at the history of a few women
run family companies and some of the prominent family
women who served on the boards of family companies. We
also tried to put together from publicly available infor-
mation the basic education qualifications and professional
background of the women of power and influence in the
corporate world.
The purpose of this study is to provide a data based
understanding of the involvement of women on the boards
of Indian companies. Such empirical work may raise
a number of issues and provide a base for further research.
Findings e the macro picture
The major findings from our study are presented in the
following sections. Table 1 details the main findings.
Fig. 1 derived from Table 1 presents the total number of
directorships held by women from 1995 to 2007.
Thenumberofdirectorshipsheldbywomenincreasedfrom29
in 1995 to 67 in 2007. The overall trend is increasing andpositive.
Fig. 2 again taken from Table 1 provides the data on
women directorships as a percentage of total directorships
for the sample of 166 companies.
The percentage of women directorships in the total
number of directorships for the period 1995 to 2007 shows
an increasing and positive trend. This percentage increased
from 1.66% in 1995 to 3.63% in 2007.
Though this is encouraging, the data makes clear that
women are not well represented in the higher echelons of
corporate India.
The Standard Chartered Report mentioned earlier
(Banerji et al., 2010) compares their findings on percentage
Figure 1 Total number of directorships held by women from 1995 to 2007.
Figure 2 Women directorships as a percentage of total directorships.
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with those of a few countries for which some data is
available. According to this report India is the lowest with
5.4% of the directorships being held by women.
By contrast Canada (15%), USA (14.5%), the U.K. (12.2%),
Hong Kong (8.9%) and Australia (8.3%) all have higher
percentages. Our findings suggest that the percentage of
women directorships in India has even been lower than the
Standard Chartered Bank figure of 5.4%.4
We also compared the number of board directorships
held by each woman director with the number of board
directorships held by each male director. The results are
presented in Fig. 3.
The number of directorships per woman director
increased from1.04 directorships perwomandirector in 19954 3.63% is a far cry from the 33% or even the 50% representation
based on the man woman ratio that is talked about in any discussion
on the representation of women in India. See reference 3 p.17 of the
report for the data on other countries. The Standard Chartered Bank
Study is limited to the top 100 companies listed on the Bombay Stock
Exchange. Our study is more comprehensive as it covers the whole of
the country.to 1.34 in 2007. By contrast the number of directorships per
man director remained more or less constant at 1.19.
The data seems to suggest that during the initial part of
this period from 1995 to 2002 women seemed to lag behind
men in the number of directorships per person. However
after 2002 women seemed to have forged ahead and appear
to be better connected. Howeverwe should be careful in this
interpretation of the data. If women, because of their sex,
face greater barriers to achieving success in the corporate
domain, they have to be far more gifted and persistent in
order to be able to make it to the higher levels of the
corporate world. There could therefore be a kind of self-
selection bias in our sample. The number of women directors
is also significantly less than the number ofmendirectors and
this could also result in some bias. The data would suggest
that in India, post 2002, on an average, a successful woman is
more connected than the successful man.
For the entire period from 1995 to 2007 women held only
621 directorships out of 23525 directorship positions in all.
This is only 2.64% of the directorship positions (Table 1).
Out of 166 chairperson positions women never held more
than three chairperson positions in any one year.
The maximum number of directorships held by any
woman director varied between two and three. By
Figure 3 Comparison of board directorships held e women and men.
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than five and very often seven to eight directorship posi-
tions during this period. The year 1997 was an exceptional
one as far as women were concerned. Lalita Gupte,
a member of the ICICI Bank board held five directorships in
this year.
Onehundredandsixteen individualwomenaccounted forall
thewomen directorships (621 directorships) during this period.
Howdowomenbecomedirectors of companies?
We also investigated the kinds of companies that were
providing directorships to women. The data naturally lent
itself into the following classifications:
 Women directorships that were provided by public
sector companies
 Women directorships that came about because of
family connections or family obligations
 Women directorships that came about because of
support from various financial institutions including
private sector banks
 Women directorships that could be attributed to
professional or other reasons.
Table 2 provides details of the year-wise breakup of all
women directorships under the above four groupings orTable 2 Category wise breakup e women directorships.
1995 1996 1997 1998 1999 20
Public sector 15 17 16 15 16 9
Family 8 12 11 12 15 16
Private banks þ funders 3 4 8 8 9 9
Others/Professional 3 3 2 3 5 5
Total 29 36 37 38 45 39
Table 3 Category wise breakup e women directorships percen
1995 1996 1997 1998 1999 20
Public sector 52% 47% 43% 39% 36% 2
Family 28% 33% 30% 32% 33% 4
Private banks þ funders 10% 11% 22% 21% 20% 2
Others/Professional 10% 8% 5% 8% 11% 1
Total 100% 100% 100% 100% 100% 10categories. Table 3 provides the same data in the form of
percentages.
Fig. 4 depicts the number of directorships under the
above categories in the form of a trend.
The same data is plotted in terms of percentages in
Fig. 5.
Public sector directorships occupied by women
increased marginally from 15 in 1995 to 18 in 2007 but
declined in percentage terms from 52% of all women
directorships in 1995 to 27% of the directorships in 2007.
The most prominent contributors to the public sector
directorships were the public sector banks. Out of the total
of 206 women directorships provided by the public sector
for the period 1995 to 2007, 98 directorships or 48% of the
public sector women directorships were provided by the
public sector banks. Public sector banks also accounted for
16% of all women directorships during 1995e2007.
Women who became directors through family ties also
show an increasing trend both in numbers (from eight in
1995 to 23 in 2007) as well as in percentage terms.
Family linked directorships for women increased from
28% of the directorships in 1995 to 34% of the director-
ships in 2007.
The numbers as well as the percentage of women direc-
tors under the ‘professional/other’ category also show an
increasing trend from three in 1995 to 14 in 2007 or from 10%
of the women directorships in 1995 to 21% in 2007.00 2001 2002 2003 2004 2005 2006 2007 Total
15 15 18 17 18 17 18 206
18 17 16 16 20 22 23 206
7 7 10 12 12 13 12 114
10 9 10 10 10 11 14 95
50 48 54 55 60 63 67 621
tages.
00 2001 2002 2003 2004 2005 2006 2007 Total
3% 30% 31% 33% 31% 30% 27% 27% 33%
1% 36% 35% 30% 29% 33% 35% 34% 33%
3% 14% 15% 19% 22% 20% 21% 18% 18%
3% 20% 19% 19% 18% 17% 17% 21% 15%
0% 100% 100% 100% 100% 100% 100% 100% 100%
Figure 4 Women directorships e the trend 1995 to 2007.
Figure 5 Percentage of women directors in different categories.
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institutions including their directorships in private compa-
nies showed up and down fluctuations during this period.
From three directorships or 10% of the directorships in 1995
the percentage of women directors under this category
increased to nine directorships or 23% in 2000. It then
declined to 17% by 2005 and has been growing from there
to reach 21% of the directorships in 2007.
Of the total of 114 women directorship positions held by
funding institutions, 56 positions in companies were held by
one bank e ICICI Bank. In addition to these positions with
private companies that come with financial support, ICICI
Bank also had on its own board 24 board positions assigned to
women for the period 1995 to 2007. HDFC andHDFC Bank also
had 23 board positions assigned to women. When the total
ICICI contribution is taken we find that ICICI alone accounts
for 80 women directorships or 13% of all women directorships
for theperiod 1995 to2007.HDFCandHDFCBank also account
for a large number of women directorships. These director-
ships are however largely confined to the boards of only these
two companies and do not extend to other company boards.
Public sector banks and ICICI together account for 29% of
all women directorships for the period.
Table 4 provides a list of the most connected women
directors derived from our data set. The ranking is based on
the total number of directorships held by them for theperiod 1995 to 2007. Only the data up to rank 10 is pre-
sented in the table here.
Rajashree Birla, the wife of Aditya Birla and mother of
Kumara Mangalam Birla tops the list followed by Lalita
Gupte of ICICI Bank who is ranked second. Tarjani Vakil of
EXIM Bank is third with Chanda Kochar of ICICI Bank and
Anita Ramachandran in joint fourth place. Ms. P. Bolina
from the Department of Economic Affairs of the Ministry of
Finance occupies the fifth position.
We can see that these rankings of women directors are
dominated by family connections or by positions in insti-
tutions of power such as banks and other regulatory bodies.
Our data set of companies does not seem to have any
woman director who started out as a first generation
entrepreneur and achieved notable success. The challenges
and barriers to success such women confront maybe
somewhat different from the challenges that women with
family or institutional connections face.
We therefore thought an interview with a first genera-
tion woman entrepreneur who has achieved notable
success in the corporate world would offset this weakness
of our research. The interview with Ms Kiran Mazumdar
Shaw the Chairperson of Biocon Ltd that follows will, we
hope, provide a deeper and more nuanced understanding of
the various challenges faced by women in their pursuit of
careers in the Indian business world.
Table 4 Top ten women directors.
Name of woman director Directorships Companies Power
1995e2007 1995e2007 Rank
Smt. Rajashree Birla 36 3 1
Smt. Lalita D. Gupte ICICI nominee 24 7 2
Ms. Tarjani Vakil EXIM Bank 20 3 3
Mrs. Chanda Kochhar ICICI nominee 16 4 4
Ms Anita Ramachandran 16 2 4
Ms. P. Bolina Dept of Economic Affairs 16 3 5
Mrs. Renu Karnad HDFC nominee 15 3 6
(Mrs.) Priyamvada Birla Chairperson 14 2 7
(Mrs.) Nandini Nopany 13 1 8
A. R. Aga (Mrs.) Chairperson 13 1 8
Dr. (Mrs.) Mangalam Srinivasan 13 1 8
Mrs S H Master 13 1 8
Mrs. Nita Puri 13 1 8
Dr. Manjula Subramaniam IAS 12 2 9
M. P. Pudumjee (Mrs.) Chairperson 12 1 9
Ms Rama Bijapurkar 12 2 9
Smt. Preetha Reddy 12 1 9
Smt. Satyawati Jain 12 1 9
Smt. Neeta Mukerji (ICICI) 11 2 10
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Chairman & Managing Director, Biocon Ltd
By Anitha KurupKiran Mazumdar Shaw heads India’s leading biotech-
nology enterprise, Biocon. Under her stewardship,
Biocon evolved from its inception in 1978 as an indus-
trial enzymes company to a fully integrated bio-
pharmaceutical enterprise encompassing a well
balanced business portfolio of products and services
with a research focus on diabetes, oncology and auto-
immune disease. During this transition, Biocon has
established two subsidiaries: Syngene (1994) to provide
development support services for discovery research
and Clinigene (2000) to cater to services in clinical
development.
A successful technocrat of global standing, Kiran
Mazumdar’s pioneering efforts in biotechnology have
drawn global recognition both for Indian industry and
Biocon. She chairs Karnataka’s Vision Group on
Biotechnology and has served on the Board of Science
Foundation, Ireland. She is also part of the Prime
Minister’s Council on Trade & Industry in India and the
US-India CEO Forum.
Kiran Mazumdar is the recipient of several prestigious
awards including the Padmashri (1989) and the Padma
Bhushan (2005), for her pioneering efforts in industrial
biotechnology. She has been recently voted by Nature
Biotechnology as The Most Influential in Bio-business
person outside Europe and USA.
Source: www.biocon.com/docs/KMS-Profile_091109.pdfAK: Let me start off with the question that most of us
feel like asking you. You are a woman in a man’s world.
KMS: I don’t feel like that anymore. If you had asked me
this question maybe thirty years ago, I would have felt like
that. But today, I just look at myself as a business leader in
India who is facing the same challenges and has the same
global aspirations as other business leaders. We are asking
the same kind of questions about development.
AK: When you entered this field of entrepreneurship,
the number of women must have been much fewer.
KMS: So, that’s why I said, if you had asked me this
question thirty years ago when I started the company, I
would definitely have said yes. I felt like a pioneer in many
ways because I was pioneering biotech. I was quite
a pioneer even in the fact that I was one of the very few
women pursuing an entrepreneurial path. I had huge
credibility and perception challenges to overcome because
women were few and far between, and there was a certain
perception about women in business. I was considered to be
high risk in terms of lending to or working for.
But today things have changed. I think women are well
accepted in the business world. You see a large number of
women playing leadership roles in business and there is
a very large acceptance of the fact that women are
competent, that women are very good business leaders. I
certainly think that there are no such perception problems
today.
AK: You were a first generation entrepreneur. Was it
a family lead that helped you to become an
entrepreneur?
KMS: I was certainly a first generation entrepreneur and
I had no business family background. My father was very
proud of the fact that I decided to pursue a business career.
He said, ‘I never had the guts to do it but I am so glad that
you have.’ He had tried his hand at business earlier and
failed. So he was impressed that I was ready to venture out
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a path and hoped that I would succeed.
AK: Why did you start your career in the brewing and
malting industry?
KMS: My father was a brew master at United Breweries
and that’s the business he tried to set up, a malting busi-
ness. Since I wanted to pursue something in applied
science, he said, ‘When I visit Indian breweries I find that
we are short on technological skills. Brewers should be
technically savvy, so why don’t you pursue a brewing
career. There are very few technically competent brewers
and I am sure you can do very well.’ That’s how I did the
programme and qualified as a Master Brewer from Ballarat
University, Australia in 1975.
AK: Looking back at your career of thirty years, how
did you bloom as an entrepreneur?
KMS: First and foremost, when you do something so
differentiated, and when you are willing to stick with it,
you evolve. It is a hands-on learning experience; you are
a self-taught business person. When you are self-taught,
you are willing, like a sponge, to absorb everything. You
want to succeed, you want to do things which make your
business successful. I think every first generation entre-
preneur who is successful is very committed, because you
have a sense of challenge, a sense of purpose and that helps
you to evolve. My sense of purpose was that I wanted to
prove that biotechnology is a very good business. I also
wanted to create a research environment and a research
led business. I wanted women to pursue research as a very
important vocation and as a very important career path.
And I wanted young scientists in India to look at Biocon as
a very important career path for them. So with that kind of
sense of purpose, I started building my company.
AK: When you started this company, you tied with
Biocon Biochemicals Ltd of Ireland. Why Biocon
Biochemicals of Ireland? Was it accidental?
KMS: When I came back as a brew master, I couldn’t get
a job only because I was a woman! And then I met the
founder of Biocon, an Irish biotechnology company, who
wanted to set up a venture in India and was looking for
a partner. Biocon was an industrial enzymes company
where most of their enzymes were designed for the brewing
industry. Being a brewer, I was thought to be a good
potential partner. My failure to get a job as a brewer, made
me accept this opportunity. That’s why I call myself an
accidental entrepreneur. I never really wanted to be an
entrepreneur but once I got into this, I started building the
company and I owe this to my Irish partner. Without this
accidental encounter, I might have never started my
business!
AK: You started off as an enzyme company and now
you have moved to bio-pharma products. Was it
a conscious transition?
KMS: It was a conscious transition because in the early
90s, I realised that the enzymes business was only going to
take me to a certain size. I was focused on developing
speciality enzymes which would not allow me to build scale
or size. I was a global player, but the global enzyme
opportunity for my kind of enzymes was very small. As you
develop and evolve as an entrepreneur, you suddenly start
looking at yourself and assessing where you would like to
be. I realised that if I really wanted to build a company ofscale and size, then I had to transform my business. And
that’s when I realised that I could leverage a lot of the
technology that I had developed for enzymes to bio-
pharmaceuticals. Bio-pharmaceuticals was the area and
the business that I could certainly leverage to take me to
that scale and size.
AK: You had shares with Unilever and then you moved
off to bio-pharmaceuticals?
KMS: When I decided to get into bio-pharmaceuticals I
realised that I didn’t need Unilever as a partner because
they were more into foods which dovetailed nicely with
enzymes but I wanted to move away from enzymes. Since
Unilever was not interested in bio-pharmaceuticals, I sug-
gested to them to sell back their shares to me on the
understanding that I would still supply them with enzymes,
if that was important. This came at a time when Unilever
itself was selling its entire speciality chemicals business to
ICI. I did not want to go with ICI. And since I had pre-
emptive share purchase rights, I enforced it.
AK: When one looks back at the drugs you produced, it
is interesting to note that you were doing multiple things
over the last thirty years. You also do work in the area of
innovation. What was your model?
KMS: There is a method in that madness because when
we decided to transform our business into bio-
pharmaceuticals, we did it with a very solid rationale.
There was a rationale as to why we chose certain areas. For
instance, all our generics in the small molecule area are in
the area of fermentation derived small molecules like sta-
tins and immunosuppressants. Starting with a portfolio
approach, we looked at some of the inherent technologies
that we had for enzymes, which helped us to develop the
insulins portfolio. To make a strategic entry into the bio-
pharmaceutical business, we decided to pursue chronic
diseases. We started with insulins largely leveraged from
technology. Once we got into insulins as a portfolio we went
into insulin analogues based on the technology platform of
Pichia. After committing ourselves to novel enzymes, we
decided to leverage our innovation psyche, our innovation
ethos to get into novel programmes. We decided to look at
programmes that have chronic therapies because that itself
gives us a good business model to focus on. Unlike most
Indian companies, who are into everything, we decided to
look at chronic therapies such as diabetes, immunosup-
pressants, nephrology, cancer and auto-immune disease.
Once we thought we were good at microbial fermentation,
wewanted to becomeexpert inmammalian cell culture. That’s
how we chose cancer and auto-immune diseases through
monoclonalantibodies.Oncewedecidedonnovelprogrammes,
we found the technology and the programme in Cuba.
AK: Your innovation model seems very interesting. at
one level, you have the breakthrough innovation ..
KMS: We want to have four buckets of innovation.
(See Fig. 6 e the Biocon Innovative Matrix) We start
with investing in experimental innovations e breakthrough
innovation starts with experimental innovation. For
instance, today in experimental innovation, we are devel-
oping cancer vaccines. We started with oral insulin as an
experimental innovation. Now, it’s heading towards break-
through innovation if it works. We are doing experimental
innovation with Amylin in developing a novel anti-diabetes
drug that targets both obesity and glucose control.
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For instance, in the field of bio-similars, we started with
insulins and went on to insulin analogues, which was
a simple sort of innovation. Then we moved from insulin to
antibodies which was a good evolutionary innovation and
there we have some novel programmes like BIOMAb and
the CD6. That comes into the category of next level
innovation.
We have made sure that we have always represented
these four buckets and we invest accordingly. We start with
small investments in experimental innovation which we
realise will require large investments when it comes to the
breakthrough phase, which is what we end up doing. In
incremental and evolutionary innovation, because it is less
risky, you are willing to invest more. Finally, it is about
unlocking that pipeline which is based on all these inno-
vations in a periodic manner.
AK: Looking at this model, in the context of oral
insulin, are you holding it back from the market .
KMS: No, please understand that when you develop
a novel programme like oral insulin, there is a lot of clinical
development to be done. We are not holding it back. When
you take on huge risks like this kind of innovation, you need
to also mitigate the risks. We mitigated the risks by doing
a large part of the innovation in India. In the process, we
learnt a lot about the drug. We know the drug works exactly
like we expected it to work. But we also got a huge placebo
effect because it is well-known that when you do trials in
India, patients become far more disciplined about
managing their disease than when they are not in a clinical
trial.
Now we are looking for a global partner with whom we
will develop the programme to the next level. So it will take
at least a few years before it actually completes the clinical
development and then we can take it to market.Figure 6 Biocon inAK: I was just wondering, had you been about twenty
years younger, would you have taken the risk of taking it
to market earlier? Have you become more careful with
the kind of learning you have had?
KMS: No, you cannot do that. When you take on a global
partner, they don’t want you to fragment the product
positioning opportunity. You cannot position the product
differently in different markets. Once you decide on
a global strategy, you have to be very focused and clear on
how you want to position the product. That’s why it’s
important not to be in a hurry just to launch it in the Indian
market. When there is no other way of positioning
a product, you don’t mind taking the early entry strategy
into India. But when you know the product has a thera-
peutic advantage over insulin, and you want to claim that
premium, you have to be careful that the story is the same
globally.
AK: When you look back at some of the things that you
have undertaken at the company level, was there any
strategy that you had when you entered your profes-
sional life? How did the journey pan out?
KMS: No, I have been a self-taught entrepreneur who
has learnt along the way, who has evolved along the way.
You start building strategies only when you reach critical
mass. You go through different phases. I think for the first
two or three years, I was just learning my way about,
learning to become an entrepreneur. It was a survival
phase because you are just learning to keep afloat and
grow your business. In the first 10 years, my learning
phase, I was very focused on learning the technology,
applying the technology and commercialising technologies.
The next 10 years, the second phase, were about
leveraging those technologies and building scale on them.
The third phase, the transformational one, was about
transforming my business by leveraging all thenovation matrix.
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business itself. And now that I have transformed the
business, the next is about how to build brand equity on
products. So now I am getting into that product phase
where I want to see what the products and technologies
are that will build brand Biocon.
AK: You actually have gone through these three phases
but when you are moving into the brand equity phase,
you are also taking your earlier phases with you.
KMS: Absolutely. You culminate that into a huge
critical mass and make that as your solid foundation and
that is what will build your brand. Depending on how
complex your business is, you can create a very strong
foundation in five to ten years. But in our case, we have
taken a very long time because for the first twenty
years, we were building our brand on enzymes. And we
suddenly decided that enzymes were not the right thing
for us, and spent the next ten years changing the busi-
ness to bio-pharmaceuticals. Now, we have built a very
strong foundation which will help us to use this as
a launch pad as we build the next phase, which is really
about building brand equity for the company based on
bio-pharmaceuticals.
I have always used technology as my platform and I have
always wanted to be very strong in technology as with that
base, the rest is easier.
AK: What were the turning points in your long career
with Biocon as an organisation?
KMS: My first turning point was that I developed a home
grown technology for enzymes based on solid state
fermentation, which I could scale up and commercialise. I
learnt a lot in the process because we had lot of failures.
But once we got it worked out, I was able to quickly
leverage that to not only pay back my investments but also
to build a very strong recognition for Biocon as a strong
technology player in enzymes. Some of the enzymes that
were developed using that technology are still market
leaders, even for the people we sold it to.
The next turning point was when we transformed our
business from enzymes to bio-pharmaceuticals and that
inflection point was extremely important because it also
coincided with our buying back and becoming independent.
The third inflection point was our going public, in 2004,
when we awoke to the value that we had created through
our innovation and the technologies that we have devel-
oped over the last twenty-five years. Our next inflection
point was our Pfizer deal, which again told us that we were
continuing to create very rich value and that the innovation
pipeline was paying off for us. While I believed in that
innovation pipeline, initially, people did not buy into it. But
I managed to get investors to buy into the concept that we
were creating huge asset value in our innovation pipeline.
Our venturing into the services business with Syngene
and Clinigene was a real important inflection point for me
because I did it on a hunch. Since the software services
sector was doing very well, I thought why can’t I do
something similar in research services. And that’s how I
started Syngene. That was also pioneering because we were
rated first in Asia to apply this research services model. Our
partnership with Bristol Myers/Squibb (BMS) was an impor-
tant inflection point. The next one, which is beginning to
pan out for us, is our branded formulations.AK: When you struck the deal with Pfizer, you entered
the global market. Initially, you were looking at the
domestic market, wasn’t it?
KMS: Not just domestic, we were also looking at frag-
mented markets in markets where the regulatory hurdles
were not so steep, such as in Egypt, Mexico. Brazil and
certain parts of South-East Asia. But suddenly the global
opportunity became apparent to us because of Pfizer. As an
entrepreneur, I have also believed that partnership is a very
powerful strategy in research and marketing. I have, unlike
most other companies which have gone in for acquisition as
a way of making global impact, believed that partnering
can make an equally good global impact and faster for
a company like us.
Most people look at partnering very differently. They
only look at joint ventures which, according to me, never
work. But in our partnering with Mylan, Pfizer, Amylin,
Bristol Myers/Squibb (BMS) and others, we worked out a very
strong partnering model. And that partnering model is
based on good programme management, good joint steering
committees that manage the partnership, and things like
that. I think that’s what made us very strong. Our venturing
into research services with Syngene and Clinigene, led to our
partnering with our customers. We have a very strong part-
nership with BMS which has become a very important inte-
grated research partner. That has allowed us to look at
integrated research services, which is another step forward
for us because that changed our business model in research
services as the integrated service offering is a much higher
value business.
AK: Do you think the potential of such customised
research is big?
KMS: It’s huge because if you look at it today, already
the pharmaceutical industry is externalising almost close
to a quarter of its research budget. It is estimated that in
the next 10 years, 50% of the research will be externalised.
So, it’s a huge business and considering that budgets for
research run into billions for companies, it is becoming
a very large business opportunity.
AK: To talk about another sphere of your life, how
have you been able to manage your home and work
balance?
KMS: There is no work-home balance! I think people are
kidding themselves if they think they can balance it equally.
Work takes up most of your time. You have very little for
home. I don’t think people should even look for a work- life
balance.
AK: When you reflect on your career, when has it been
easier for you to give a little more time on the home
front?
KMS: Rather than a home-work balance, I would look at
how much time you have for your own personal needs and
how much time you have to devote to your company needs.
That’s the balance I strike. I would say that till I went
public, I had a 50e50 kind of balance. I had enough time to
do a lot of things I wanted and enjoyed. I used to play golf. I
used to go on holidays. I used to spend a lot of time with my
friends. Today 10% of my time is all I get to myself. The rest
of the time is for the company. That’s because you owe so
much to your stakeholders, so the pressure is huge. I don’t
have much time for myself and it becomes very difficult,
especially when you are in the public eye, where everyone
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sions and so on. It is very difficult to tell people, listen I
want some time with my family. People don’t realise how
much of a stress factor that is. Of course, you learn to
handle this. I have given up golf completely. And I have very
short vacations.
AK: How long do you see things going this way?
KMS: Till I retire or wind down. And I think every single
business leader in this country has the same problem.
AK: Do you see yourself getting busier with your
company over the next decade?
KMS: You will be busier because you will have
a different set of challenges, the challenge of scaling up,
of managing more people. You constantly have the chal-
lenge of making sure that you remain competitive, that
you are on the right growth trajectory, that all your
stakeholders are happy with how you are managing the
company. It is a big challenge. So, obviously I’m going to
be spending more and more time addressing these
challenges.
AK: What are your aspirations? What are the things you
want to do which you did not perhaps have the time to
do?
KMS: My main aspiration is, how do I take a new block
buster drug to global markets with a ‘Made in India’ label. If
I do that I would really feel I’ve accomplished something.
AK: What are your hobbies, your interests?
KMS: Art is a strong interest for me, though I don’t have
time now to go for art exhibitions. I also involve myself in
certain civic activities and I am very concerned about
the haphazard development taking place in our country, in
my city. I am engaged with certain groups in Bangalore
where we try to influence development and I take an
active role in that. I have a CSR interest in the Biocon
Foundation where I have focused on micro-health insur-
ance and programmes in sanitation and education. Of
course, I am very involved with the Mazumdar Shaw Cancer
Centre and cancer is an area which I am really very
interested in. I have also recently decided to lend support
to Tata’s cancer effort as well. I am very interested in
translational research and I want India to become good at
translational research.
AK: What according to you are factors responsible for
women not being able to reach the top?
KMS: I think it is societal prejudices, a lack of self-belief
e women not being confident enough and strong enough to
stick to what they want to do.
AK: What are the things that you have put in to your
organisation as a leader to help keep people in the
organisation? A large number of organisations have
people who don’t stay on, they have a huge turnover.
KMS: We also have a huge turnover. And that’s where I
think the challenge is for most companies because we
believe the employee retention is directly linked to job
satisfaction. Employee retention is also about how effi-
ciently people manage their own jobs. When you manage
your job very efficiently, job satisfaction is much higher. If
you don’t manage your job efficiently, there is a lot of
stress related to your job and that’s what tempts people to
jump ship. Of course, these days there is the lure of
unrealistic salaries that also get people to jump ship. But I
think people need to understand that they are destroyingtheir careers if they don’t develop experience and exper-
tise. Job hopping is very good in the short term, but very
bad in the long term because it doesn’t help you to develop
expertise.
AK: Have you also addressed at the organisational
level, career aspirations in terms of career growth?
KMS: We certainly do. Career aspirations can only be
dealt with in a mature way, if people are not constantly
looking for their next new job. If people know what they
are doing in terms of their careers, you can develop
a very strong career path for them. We can do it with the
senior level people but at the junior level, people are
looking at various sectors as to who gives them the best
salary package. As an organisation, the only way we
need to develop people in their career roles, is to be
very clear about roles and responsibilities. If people are
very clear about their roles and responsibilities, you can
appraise and evaluate them objectively. Then you can
carve out a more meaningful career path for such people
and they will have a lot higher job satisfaction and job
achievement. And more than anything else, in this
country and in this company, I want to focus on how you
get people to become a bit more selfless. People are
generally looking out for what their organisation can do
for them; there’s never any discussion about what they
can do for the organisation. So we are trying to get
people to understand it’s quid pro quo. The organisation
is investing a lot in you but what are you doing for the
organisation? What are you doing in terms of growth and
productivity?
AK: You will find that there is a variation of attitudes
in terms of generation .
KMS: In the past there was a womb to tomb career path.
Most people looked at one company and said I am willing to
grow with this company and I trust the company to do
whatever it can for me and I will give it my best. Today, the
job market is seen as exciting, and people stay with
a company just to improve their CVs and then pursue
greener pastures that offer higher salaries and designa-
tions. But it is self inflated worth. People need to under-
stand what their own capabilities are. That recognition has
to come.
AK: Having stayed in the area of entrepreneurship, as
a woman, did you have role models?
KMS: I have been inspired by several interesting
people. One is Mr N Vaghul, former Chairman if ICICI Bank,
who has been a mentor to me; Dr Bala Manian, who is
a serial entrepreneur in the Bay area; Dr Devi Prasad
Shetty, the founder of Narayana Hrudayala in Bangalore e
he has inspired me because I really like his business
model; Ms Shikha Sharma from the banking sector e
another person who thinks out of the box; Dr R A
Mashelkar of CSIR; Mr Narayana Murthy and Mr Azim Pre-
mji; I am also inspired by people like Vijay Mallya, who has
dared to do things differently. He has built a great brand
out of Kingfisher. I always admire people who are change
makers, who do things differently, who take risks, who
have done things in a daring way. Two self made women
entrepreneurs whom I admire a great deal are the late
Anita Roddick who made Body Shop such a global brand
and Yang Mian Mian head of the Chinese white goods
company, Haier.
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KMS: I did say Shikha Sharma, Anita Roddick and Yang
Mian Mian. I also admire Ela Bhatt for the way she has
organised SEWA. These are the people I have learnt a lot
from, just by studying some of the things they do.
AK: What would be your take home lessons for aspiring
woman entrepreneurs, if they want to start?
KMS: First and foremost, they have to learn to identify
opportunities. And then they have to conceptualise and
build on those opportunities. It is not just about getting an
idea. You have to think about it in a very disciplined way,
about how you will conceptualise, build and take this idea
to the next level. And then, I think women need to network
a lot more. Women usually fight shy of networking, they are
not very confident. And they must learn to have self-belief.
Of course, one needs a lot of support e from society and
your immediate family.
Many Indian women do not get that support. Many
survive against odds and rebuild their lives. I admire such
women.
AK: But how much of a role does family support play?
KMS: A very big role. My father, my whole family, and
then my husband have been very supportive of me. But
family plays a big role, being your immediate circle, and
that gives you a lot of confidence. If everything, everybody
else supports you, it’s great. But if your family supports
you, you get that extra courage and strength.
AK: This has been a great conversation. Thank
you very much for sharing your thoughts on all these
issues.Conclusions
A fairly large proportion of women directorships in the
corporate world seem to represent family interests. These
seem to have become more important during the period of
our study.
Though entry of women into the higher echelons of the
corporate world is getting easier they still constitute only
a miniscule fraction of corporate boards. Similar problems
confront women in other parts of the world. However India
seems to be much further behind many other countries for
which such data is available. This pattern that we see is
very similar to the pattern we see for women professionals
in the fields of science and engineering. The absence of
empirical data both for the corporate world as well as for
women scientists and engineers at the national level maybe
the reason why this has not received enough attention in
India.
Barriers to success seem to be even more pronounced for
women entrepreneurs promoting startup companies than
for women pursuing professional careers in the corporate
world.
Though on an average, women directors appear
better connected than the average male director, the
most well connected male director is still far more influ-
ential than the most well connected woman director. This
can be because this is unchartered territory for women
entrepreneurs.Once initially higher thresholds are crossed, the chal-
lenges faced by both women entrepreneurs and women
professionals in companies appear to be similar to those
confronting men. There are only business specific problems
that have to be solved in which women have relatively less
experience than men.
Like in the case of men, success in the pursuit of an
entrepreneurial or professional corporate career requires
a major commitment of time and effort. This may increase
as women move up the entrepreneurial or corporate ladder.
While organisation practices could facilitate such involve-
ment to a limited extent our research does not reveal any
women specific provisions that organisations/companies
have introduced. Successful women in the corporate world
or in the field of science and engineering do not seem to
articulate any need for any such special provisions for
women other than reducing tacit inbuilt male bias
against women pursuing an entrepreneurial, a corporate or
a science career.
Support systems, particularly from family e parents and
spouses, appear to be critical for success. As women
advance in their careers, business commitments consume
a larger amount of time leaving very little time to attend to
personal and family needs. In this aspect there do not
appear to be any major differences between men and
women, at least in the Indian context.
Our research reveals that private sector as well as public
sector banks are responsible for a very large proportion of
women directorships. A deeper understanding of why this is
so maybe a useful research exercise.
The research also suggests that as women achieve
success in their chosen career paths they also become more
influential and become members on more corporate
boards. This is very similar to what happens to men direc-
tors except that the most successful men seem to be better
connected than the most successful women. However this
maybe more symptomatic of the period 1995 to 2007 than
current trends. Kiran Mazumdar Shaw for e.g. after the
major successes achieved by Biocon has become a member
of several boards since 2006. She seems to be matching or
closely matching the networking capabilities of her male
counterparts. Whether this is an isolated occurrence or
a new trend needs to be researched further. Becoming
members of such elite clubs may become increasingly
important as women transition into positions of leadership
in the business world.
However, women still have a long way to go before they
are able to catch up with their male counterparts.
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